BpV(HOpic) is a potent and selective inhibitor of PTEN with an IC50 of 14 nM. Nanocarrier-BpV(HOpic) has neuroprotective activity.
性状
Solid
IC50 & Target[1][2]
IC50: 14 nM (PTEN)
体外研究(In Vitro)
BpV(HOpic) (1 μM) treatment increases cell proliferation and decreases apoptotic rate in MG63 cells received Cisplatin treatment.
Bpv(HOpic) (1 μM) enhances migration of C2C12 myoblasts and is associated with activation of PI3K/AKT and MAPK/ERK signalling pathways.
BpV(HOpic) (1 μM; 48 hours) promotes the initiation of swine follicle growth and development, similar as in rodent species and humans.
Nanocarrier-BpV(HOpic) enhances axonal outgrowth of neurons.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
BpV(HOpic) (0.05 mg/kg; i.p.) at reperfusion ameliorates liver ischemia/reperfusion (I/R) injury in vivo.
BpV(HOpic) (200?μg/kg; i.p.) exacerbates renal dysfunction and promotes tubular damage in mice with ischemia/reperfusion injury (IRI).
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male Wistar rats are subjected to partial hepatic ischemia
Dosage:
0.05 mg/kg
Administration:
I.p. injections at the start of reperfusion
Result:
Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation.
Animal Model:
Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia
Dosage:
200?μg/kg
Administration:
I.p. injections 1?h before ischemia and then administers every 6?h after ischemia for 24 hr
Result:
Raised the level of serum creatinine and blood serum urea nitrogen.